Publication details

Současný stav léčby anaplastických gliomů v České republice

Title in English Current State of Art of the Therapy of WHO Grade III Gliomas in the Czech Republic
Authors

KALITA O. KRAMÁŘ F. NEUMAN Eduard HRBÁČ T. BOLCHA M. BRABEC R. JANČÁLEK Radim ŠTĚPÁNEK D. BLÁHA M. JUREK P. MALÚŠKOVÁ Denisa STRENKOVÁ Jana

Year of publication 2015
Type Article in Periodical
Magazine / Source Česká a Slovenská neurologie a neurochirurgie
MU Faculty or unit

Faculty of Medicine

Citation
Field Neurology, neurosurgery, neurosciences
Keywords anaplastic gliomas; general management strategy; radical resection; chemoradiotherapy
Description The aim of our paper is to evaluate treatment results for WHO grade III gliomas in the Czech Republic. We performed an assessment of a sample of patients from the glioma tumor DoIT registry. Data on 226 patients diagnosed with WHO grade III gliomas between 1 January 2007 and 31 December 2012 in ten centers were available for statistical analysis. We failed to prove an effect of gender on overall survival. However, a positive effect of patient age, oligodendroglial tumor component (median survival - 45.3 months), extent of resection (median survival - 25.4 months), chemoradiotherapy vs. radiotherapy alone (median survival - 33.1 vs. 11.6 months) was shown as well as a synergic effect of total tumor resection plus chemoradiotherapy on overall survival (median survival - 36 months). Temozolomide was the first-choice chemotherapy regimen in all centers; PCV chemotherapy was initially administered in one case of oligo-glioma only. The analysis also implies that implementation of cytogenetic investigation of prognostic markers (MGMT, 1p/19q, IDH, ATRX) into standard laboratory procedures is required if individualized therapy of WHO grade III glioma is to take place. WHO grade III gliomas are a very heterogeneous group of tumors with different prognosis and treatment response. Virtually all comprehensive cancer centers have appointed neuro-oncologic teams including neurologists and neurosurgeons who thus participate in establishing the general management strategy for WHO grade III gliomas.

You are running an old browser version. We recommend updating your browser to its latest version.

More info